Replimune went from an FDA rejection to a resubmission, a optimistic advisory committee vote, and eventually an accelerated regulatory approval for superior melanoma — all in lower than 4 months. The FDA nod for Replimune’s oncolytic viral remedy, Tudriqev, positions it as a extra handy various to an Iovance Biotherapeutics cell remedy that had been the one therapy on this setting.
The submit Restoration for Replimune: Accelerated Approval for Most cancers Drug Twice Spurned by FDA appeared first on MedCity Information.
